Webdisclosure.com

Search

ARIX BIOSCIENCE PLC Results of Annual General Meeting

Directive transparence : information réglementée

14/06/2021 15:55

Arix Bioscience PLC (ARIX)
Results of Annual General Meeting

14-Jun-2021 / 14:55 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


 

Arix Bioscience Plc

 

Results of Annual General Meeting

 

LONDON, 14 June 2021: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that its Annual General Meeting (the "Meeting") was held today, Monday, 14 June 2021, at 14.00 BST. At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 18 May 2021 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 10 were passed as ordinary resolutions. Resolutions 11 to 14 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's website.

 

No

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

TOTAL VOTES

% of ISC VOTED

VOTES WITHHELD

1

To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2020

61,517,202

92.76%

4,800,657

7.24%

66,317,859

50.32

2,783

2

To approve the Directors' Remuneration Report

58,196,535

92.34%

4,825,953

7.66%

63,022,488

47.82

3,298,154

3

To re-elect Giles Kerr as a Director

61,344,286

92.51%

4,964,902

7.49%

66,309,188

50.31

11,454

4

To elect Peregrine Moncreiffe as a Director

60,271,773

92.55%

4,855,144

7.45%

65,126,917

49.42

1,193,725

5

To elect Maureen O'Connell as a Director

58,841,750

90.36%

6,274,013

9.64%

65,115,763

49.41

1,204,879

6

To elect Isaac Kohlberg as a Director

58,842,050

90.35%

6,285,167

9.65%

65,127,217

49.42

1,193,425

7

To elect Robert Lyne as a Director

60,072,787

90.59%

6,236,701

9.41%

66,309,488

50.31

11,154

8

To appoint BDO LLP as auditors of the Company

61,500,167

92.74%

4,817,701

7.26%

66,317,868

50.32

2,774

9

To authorise the Audit and Risk Committee of the Company to fix the remuneration of the auditors

61,516,153

92.76%

4,804,189

7.24%

66,320,342

50.32

300

10

To authorise the Directors to allot shares

61,019,094

92.01%

5,297,239

7.99%

66,316,333

50.32

4,309

11

Authority to disapply statutory pre‐ emption rights*

59,364,402

89.52%

6,951,931

10.48%

66,316,333

50.32

4,309

12

Additional authority to disapply statutory pre‐ emption rights*

59,363,555

89.52%

6,952,778

10.48%

66,316,333

50.32

4,309

13

To authorise the Company to purchase its own shares*

61,478,596

92.71%

4,836,857

7.29%

66,315,453

50.32

5,189

14

Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice*

61,517,295

92.76%

4,803,047

7.24%

66,320,342

50.32

300

 

*Special resolutions

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 18 May 2021, which is available on Arix investor relations website.

A replay of the presentation and the Meeting will be available via webcast shortly after the event on the Company's investor relations website at: https://arixbioscience.com/investor-relations/events-presentations

 

[ENDS]

  

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 



ISIN: GB00BD045071
Category Code: RAG
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 111187
EQS News ID: 1207766

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1207766&application_name=news&site_id=symex

27/07/2021 18:05
27/07/2021 08:02
26/07/2021 18:00
23/07/2021 18:05
22/07/2021 18:07
21/07/2021 18:18
21/07/2021 08:00
20/07/2021 18:14
19/07/2021 18:18
16/07/2021 18:20